Da Silva Jorge Santos is CEO at MoonLake Immunotherapeutics (MLTX). They have made 2 open-market trades across 1 company since 2024, most recently 2026-07-10.
CIK 0001920509
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 2 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| MLTX | 2,774,893 | $26.5M |
Shares reported on the most recent Form 4, priced at the 2026-07-13 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| MLTX | SELL · 10b5-1 | 2026-07-09 | 2026-07-13 | $20.02 | $2.0M | -5.7% | -16.1% | -48.0% |
| MLTX | SELL · 10b5-1 | 2026-07-01 | 2026-07-02 | $20.03 | $957K | +4.9% | -8.6% | -38.5% |
| MLTX | SELL | 2026-04-10 | 2026-04-14 | $18.35 | $2.8M | -7.7% | -1.1% | +9.7% |
| MLTX | SELL | 2025-12-08 | 2025-12-10 | $14.87 | $3.0M | -6.6% | +28.0% | +27.0% |
| MLTX | SELL · 10b5-1 | 2024-02-27 | 2024-02-29 | $55.07 | $7.1M | -7.2% | -2.0% | -17.2% |
| MLTX | SELL · 10b5-1 | 2024-02-21 | 2024-02-23 | $55.27 | $124K | -13.1% | -0.6% | -23.2% |
| MLTX | SELL · 10b5-1 | 2024-02-15 | 2024-02-20 | $59.26 | $3.6M | -7.2% | -4.6% | -29.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.